On July 2, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the approval of new forms of award agreements by the company's Board. These agreements are designed for the grant of stock options and restricted stock units to directors, executive officers, employees, and consultants under iBio's 2023 Plan. The agreements include various terms and vesting criteria, with provisions detailing the exercise price payment methods and the treatment of awards upon termination of service for different reasons. Additionally, iBio Inc adopted an updated Code of Business Conduct and Ethics applicable to all directors, officers, and employees, replacing the previous code to better reflect the company's operations and mitigate risk. The full text of the Award Agreements and the updated Code are attached to the report as exhibits.

On July 2, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the approval of new forms of award agreements by the company's Board. These agreements are designed for the grant of stock options and restricted stock units to directors, executive officers, employees, and consultants under iBio's 2023 Plan. The agreements include various terms and vesting criteria, with provisions detailing the exercise price payment methods and the treatment of awards upon termination of service for different reasons. Additionally, iBio Inc adopted an updated Code of Business Conduct and Ethics applicable to all directors, officers, and employees, replacing the previous code to better reflect the company's operations and mitigate risk. The full text of the Award Agreements and the updated Code are attached to the report as exhibits.